According to a report from Reuters, the US Federal Trade Commission (FTC) has sought additional information from Bristol-Myers Squibb and Celgene and is focusing on the companies’ psoriasis treatments as part of its review of their planned merger, Bristol-Myers announced on Tuesday, March 26.
“The parties understand that the FTC’s review is focused on marketed and pipeline products for the treatment of psoriasis,” Bristol-Myers stated in a filing.
Celgene’s psoriasis drug Otezla brought US$448 million in sales in the quarter ended December 31. Bristol-Myers is also developing a treatment for the condition and in September reported positive results from a mid-stage trial of its plaque psoriasis drug.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 216.73.216.177
Please verify email or join us
to access premium content!
